|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 Biolargo, Inc. 10-Q 6/30/22 60:7.2M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.50M
7: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
9: EX-32 Certification -- §906 - SOA'02 HTML 20K
10: R1 Document And Entity Information HTML 69K
11: R2 Consolidated Balance Sheets (Current Period HTML 158K
Unaudited)
12: R3 Consolidated Balance Sheets (Current Period HTML 32K
Unaudited) (Parentheticals)
13: R4 Consolidated Statements of Operations and HTML 111K
Comprehensive Loss (Unaudited)
14: R5 Consolidated Statements of Stockholders' Equity HTML 120K
(Deficit) (Unaudited)
15: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 116K
16: R7 Note 1 - Business and Organization HTML 28K
17: R8 Note 2 - Summary of Significant Accounting HTML 113K
Policies
18: R9 Note 3 - Sale of Stock for Cash HTML 23K
19: R10 Note 4 - Debt Obligations HTML 41K
20: R11 Note 5 - Share-based Compensation HTML 124K
21: R12 Note 6 - Warrants HTML 49K
22: R13 Note 7 - Accounts Payable and Accrued Expenses HTML 27K
23: R14 Note 8 - Noncontrolling Interest - Clyra Medical HTML 43K
24: R15 Note 9 - Business Segment Information HTML 113K
25: R16 Note 10 - Commitments and Contingencies HTML 22K
26: R17 Note 11 - Subsequent Events HTML 22K
27: R18 Significant Accounting Policies (Policies) HTML 157K
28: R19 Note 2 - Summary of Significant Accounting HTML 71K
Policies (Tables)
29: R20 Note 4 - Debt Obligations (Tables) HTML 33K
30: R21 Note 5 - Share-based Compensation (Tables) HTML 107K
31: R22 Note 6 - Warrants (Tables) HTML 47K
32: R23 Note 7 - Accounts Payable and Accrued Expenses HTML 26K
(Tables)
33: R24 Note 8 - Noncontrolling Interest - Clyra Medical HTML 43K
(Tables)
34: R25 Note 9 - Business Segment Information (Tables) HTML 105K
35: R26 Note 1 - Business and Organization (Details HTML 49K
Textual)
36: R27 Note 2 - Summary of Significant Accounting HTML 79K
Policies (Details Textual)
37: R28 Note 2 - Summary of Significant Accounting HTML 23K
Policies - Summary of Cash Balances (Details)
38: R29 Note 2 - Summary of Significant Accounting HTML 40K
Policies - Credit Concentration (Details)
39: R30 Note 2 - Summary of Significant Accounting HTML 24K
Policies - Inventory (Details)
40: R31 Note 2 - Summary of Significant Accounting HTML 31K
Policies - Stock Options, Valuation Assumptions
(Details)
41: R32 Note 3 - Sale of Stock for Cash (Details Textual) HTML 33K
42: R33 Note 4 - Debt Obligations (Details Textual) HTML 34K
43: R34 Note 4 - Debt Obligations - Schedule of Debt HTML 36K
(Details)
44: R35 Note 5 - Share-based Compensation (Details HTML 112K
Textual)
45: R36 Note 5 - Share-based Compensation - Stock Options HTML 79K
(Details)
46: R37 Note 6 - Warrants (Details Textual) HTML 33K
47: R38 Note 6 - Warrants - Warrants Outstanding (Details) HTML 37K
48: R39 Note 7 - Accounts Payable and Accrued Expenses - HTML 31K
Summary of Accounts Payable and Accrued Expenses
(Details)
49: R40 Note 8 - Noncontrolling Interest - Clyra Medical HTML 127K
(Details Textual)
50: R41 Note 8 - Noncontrolling Interest - Clyra Medical HTML 26K
Common and Preferred Shares Outstanding (Details)
51: R42 Note 8 - Noncontrolling Interest - Summary of HTML 27K
Accounts Payable and Accrued Expenses (Details)
52: R43 Note 9 - Business Segment Information (Details HTML 19K
Textual)
53: R44 Note 9 - Business Segment Information - Segment HTML 78K
Information (Details)
54: R45 Note 10 - Commitments and Contingencies (Details HTML 23K
Textual)
55: R46 Note 11 - Subsequent Events (Details Textual) HTML 41K
58: XML IDEA XML File -- Filing Summary XML 110K
56: XML XBRL Instance -- blgo20220630_10q_htm XML 2.07M
57: EXCEL IDEA Workbook of Financial Reports XLSX 111K
3: EX-101.CAL XBRL Calculations -- blgo-20220630_cal XML 111K
4: EX-101.DEF XBRL Definitions -- blgo-20220630_def XML 1.14M
5: EX-101.LAB XBRL Labels -- blgo-20220630_lab XML 901K
6: EX-101.PRE XBRL Presentations -- blgo-20220630_pre XML 1.15M
2: EX-101.SCH XBRL Schema -- blgo-20220630 XSD 167K
59: JSON XBRL Instance as JSON Data -- MetaLinks 323± 517K
60: ZIP XBRL Zipped Folder -- 0001437749-22-020577-xbrl Zip 249K
EXHIBIT 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Charles K. Dargan II, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioLargo, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 15, 2022 |
By: |
|
|
Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/15/22 | |||
| For Period end: | 6/30/22 | 4 | ||
| List all Filings | ||||